bluuebunny/crossref_metadata_2025_split huggingface dataset:
Evolving Permian magmatism associated with arc migration in the southern Beishan Orogenic Collage, Central Asian Orogenic Belt, NW China
Authors: Hong Tong , van Staal Cees , Lin Shoufa , Santos Gabriel S. , Wang Kai 
Published: June 2023

Abstract

The Beishan Orogen contains the youngest suture in the Central Asian Orogenic Belt and is vital to understanding its terminal collision history and closure of the last vestiges of the Palaeo-Asian Ocean. Multidisciplinary evidence is provided for a close temporal and spatial linkage between the Liuyuan Complex back-arc ophiolite and the Ganquan Complex arc rocks. The Ganquan Complex mainly comprises felsic volcanic and volcaniclastic rocks and is divided into a lower and upper sequence, both of which exhibit arc-like geochemical signatures and have magmatic zircons characterized by mantle-like
δ
18
O values. Their U–Pb zircon ages range between 295 and 286 Ma and between 283 and 281 Ma, with corresponding
ε
Hf values varying from −4.2 to +1.9 and from +1.3 to +7.6, respectively, indicating a more juvenile magma source over time. The increase of juvenile isotopic signatures in the Ganquan Complex rocks is attributed to arc-trench migration, which progressively removed the arc from influences of an old arc basement contaminant and led to back-arc spreading and formation of the Liuyuan ophiolite. Cessation of the multi-phase Ganquan arc system at
c.
280 Ma coincided with the accretion of the continental Baidunzi Complex in the south.
Abstract 10309: Susceptibility-Weighted Imaging is Not Inferior to CT in Detecting Intracranial Vertebral Artery Calcification
Authors: Liu Hon-Man 
Published: June 2023

Susceptibility-Weighted Imaging is not inferior to CT in detecting intracranial vertebral artery calcification
Hon-Man Liu. Department of Medical Imaging, Fu-Jen Catholic University Hospital, Fu-Jen Catholic University, New Taipei City, Taiwan

Introduction:
Microcalcification is vulnerable and ready to rupture, and macrocalcification is more stable. CT is more sensitive to detect calcification than conventional MR. We demonstrated that the advance MR technique, susceptibility-weighted imaging (SWI), is not inferior to CT in detecting calcification of intracranial vertebral artery.

Hypothesis:
Susceptibility-weighted imaging can detect paramagnetic blood clots and diamagnetic calcification. Materials and methods: We reviewed the patients’ brain SWI imaging between January 2021 to March 2022 in our institute. The inclusion criteria were patients had SWI and brain CT done within 3 months. The exclusion criteria were poor imaging quality, insufficient study, and incomplete study. We defined that vessel wall calcification as void signal on SWI and hyper-attenuation (> or =100 HU) on CT. We compared the incidence and location of the calcification shown on CT and the void signal on SWI in the intracranial vertebral artery wall.

Results:
A total of 817 patients is eligible for this study. They were aged between 25 years to 90 years old and 393 were females. A 3.0T MR scanner was used in 486 patients, and 1.5T in 331. On CT, intracranial vertebral artery calcification was shown in 613 vertebral arteries. Susceptibility-weighted imaging could depict 98.5% (n=604) void signal at the corresponding intracranial vertebral artery segment shown on CT. Void signal on SWI is conspicuous in 12 foci that not shown as hyper-attenuation on CT.

Conclusion:
Susceptibility-weighted imaging is not inferior to CT in detecting intracranial vertebral artery calcification. SWI can play a role in the research about intracranial atherosclerosis in the future.
Abstract 10487: In vivo Efficacy of HS135, a Novel Activin and GDF Trap for the Treatment of Pulmonary Hypertension (PH) and Metabolic Syndrome (MetS)
Authors: Schang Gauthier , Poujol de Molliens Mathilde , Denis Jean-Francois , Chauvet Cristina , Brule Emilie , Schoelermann Julia , Tremblay Gilles , O'Connor-McCourt Maureen 
Published: June 2023

Introduction:
PH is a disorder characterized by remodeling of the pulmonary vasculature which causes increased pulmonary vascular resistance and ultimately right ventricular (RV) failure leading to death. MetS is a recognized risk factor for PH, particularly in patients suffering from PH associated with left-sided heart failure (WHO Group 2 PH) for which there are no approved therapies.

Activins and growth differentiation factors (GDFs) are implicated in both PH pathology as well as body composition and metabolism by genetic disease association, preclinical, translational, and clinical evidence.
HS135 is a rationally designed first-in-class activin-receptor (ActR)-based fusion protein that addresses both vascular remodeling and MetS in PH without affecting hematological parameters; hematological effects limit the dosing of other ActR-based agents.

Methods:
HS135’s ability to counteract vascular remodeling and heart failure in PH was assessed using a rat monocrotaline (MCT) model: a single dose of 60 mg/kg MCT was administered on Day 0 followed by 4 weeks of twice weekly treatment with either HS135 (1, 4, or 16 mg/kg) or vehicle. PH efficacy was assessed at end of study by echocardiography and histological readouts. HS135’s ability to improve body composition and metabolism was assessed in wild type mice by administering HS135 (1, 3, 10, 20, or 50 mg/kg) or vehicle twice weekly for 3 weeks. The effect of HS135 on hematological parameters was assessed by whole blood cell count in non-human primates (NHPs) 2 weeks following a single administration of HS135 at 3 or 30 mg/kg.

Results:
HS135 at 3 or 30 mg/kg did not lead to changes in hematological parameters in NHPs. Compared to vehicle, HS135 was effective at counteracting the MCT-induced PH phenotype in rats as evidenced by significant reductions in Fulton index and improved echocardiography parameters. In wild type mice, HS135 led to significant improvements in body composition.

Conclusions:
Contrary to other ActR-based therapies, HS135 did not lead to increases in hematocrit which would limit its dosing. HS135 was efficacious at treating PH while simultaneously improving body composition in preclinical models. Clinical trials with HS135 are expected to commence within 2023.
Abstract 12830: Significant Smoking Reduction and the Risk of Cardiovascular Disease (CVD): Prospective Results From the Framingham Heart Study
Authors: Duncan Meredith S , Freiberg Matthew S , Greevy Robert , Kundu Suman , Eden Svetlana , Ramachandran Vasan S , Tindle Hilary A 
Published: June 2023

Smoking cessation reduces CVD risk, but whether significant reduction (
>
50%) in cigarettes per day (CPD) decreases CVD risk is unclear. Some prior studies have reported no benefit but are limited by incomplete capture of smoking exposure due to few smoking assessments or short follow-up. We used Framingham Heart Study data to quantify CVD risk benefits of smoking reduction.

We included participants attending at least two exams: 3642 Original cohort starting with their fourth exam (1954-1958) and 3582 Offspring cohort starting with their first exam (1971-1975). Participants were free of CVD at baseline and were followed through 2016 for incident CVD. We updated smoking and other variables every 2 (Original) and 4 (Offspring) years, pooling cohorts for analysis. Using extended Cox regression, we compared CVD risk among 4 categories of person-time: current smoking with significant reduction (CPD reduced by
>
50%); current smoking without significant reduction (maintained, increased, or reduced by < 50%); former smokers (quit during follow up); and never smokers. Models were adjusted for sex and time-varying covariates (age, CPD, years reduced, pack-years smoked, and other traditional CVD risk factors).

Relative to the Offspring, the Original cohort was older (51 vs 44) and had a larger proportion of current smokers (49% vs 36%) but smoked fewer CPD (19 vs 23). During a median follow up of 27 years, 2327 CVD events occurred (4.3% among significant reducers). Compared to current smoking without significant reduction, significant reduction was associated with lower CVD risk (HR [95% CI]: 0.76 [0.58, 0.99]). After excluding smokers who increased CPD, the effect was similar (HR=0.80 [0.60, 1.08] p=0.14). Significant reduction was associated with higher CVD risk compared to quitting smoking (1.57 [1.24, 2.01]) and never smoking (1.45 [1.12, 1.87]).
Significant CPD reduction is associated with lower CVD risk compared to current smoking without significant reduction, but with higher CVD risk compared to quitting and never smoking. These findings incorporate extensive lifetime smoking history, including changes in smoking rate, and provide evidence for public health messaging that, while cessation is preferred, smoking reduction may also decrease CVD risk.
Abstract 12956: Pulmonary Vein Thrombosis: A Rare Complication Following Infection With SARS-CoV-2
Authors: Suresh Mithun R 
Published: June 2023

Case Presentation: 49 year old male with past medical history of hypertension who presented with dyspnea and nasal congestion of three days duration. Testing for SARS-CoV-2 was positive. ECG revealed sinus tachycardia with an incomplete right bundle branch block. D-dimer was elevated 3,388 ng/mL and CT pulmonary angiogram revealed thrombosis of a right lower lobe pulmonary vein extending to the posterior aspect of the left atrium along with consolidation in the right lower lobe concerning for pulmonary infarct versus congestion in the setting of pulmonary venous thrombosis. The patient was admitted and started on intravenous unfractionated heparin. Echocardiogram performed later in the day revealed left ventricular segmental wall motion to be globally hypokinetic with mildly reduced ejection fraction of 45%. Left atrium was severely enlarged. No thrombus could be seen in the left atrium or ventricle. Bubble study revealed no evidence of atrial septal defect or patent foramen ovale. The next day after admission, his symptoms had resolved and he was back to his baseline, so he was discharged. No supplemental oxygen was required. Heparin was transitioned to apixaban, and metoprolol succinate and lisinopril were initiated. Cardiac monitoring during the hospitalization did not demonstrate any arrhythmias. Etiology of his pulmonary vein thrombosis was ultimately felt to be due to coagulopathy secondary to COVID-19 given that the patient’s medical history was otherwise unremarkable.
Discussion: This case describes a rare complication due to infection with SARS-CoV-2. Pulmonary artery thrombi are common with SARS-CoV-2 infection, but pulmonary vein thrombi are rare. With thrombus extending to the left atrium, cardiac monitoring was performed and did not reveal evidence of atrial fibrillation or atrial flutter. With no other identifiable cause of the thrombus, the etiology was likely due to SARS-CoV-2 infection.
Abstract 13005: Tips and Tricks for Successful Trans-EVAR TAVR: Buddy Up
Authors: Ghosh Priyanka , Shah Amit , Sporn Daniel , Reitknecht Felice , Kaluski Edo 
Published: June 2023

Trans-catheter aortic valve replacement (TAVR) via tortuous iliofemoral access with prior endovascular aneurysm repair (EVAR) is challenging.
83 year old male with severe aortic stenosis and prior EVAR was evaluated for TAVR with 29 mm Edwards Sapien 3 valve. Right femoral access was planned with ipsilateral protection. CT angiogram showed EVAR with tortuosity, rigidity, and graft protrusion concerning for advancement of equipment. The right iliofemoral system was accessed using a 4F radial sheath, Judkins JR4 catheter, and 0.035” angled glide wire exchanged for Amplatz Superstiff wire. A 30 cm 6F sheath was advanced over the wire followed by additional Superstiff buddy wire. Two Proglides were deployed over two separate wires, without rewiring. To overcome friction on removing second Proglide, predilatation of the arteriotomy should have been performed with a 8-9F sheath. An 8F sheath was advanced over one of two Superstiff wires. A V18 0.018” wire was placed in the ipsilateral protect site, exchanged for a third Superstiff wire to ease insertion of the Edwards sheath. The sheath was advanced followed by successful valve deployment. After removing the delivery system, two pre-deployed Proglides closed the arteriotomy site.
Detailed planning enables operators to overcome challenges using the following strategies: 1) avoid unnecessary rewiring of the iliofemoral system by use of a 30 cm 6F sheath, 2) predilate the TAVR arteriotomy with larger sheaths prior to deploying Proglides to avoid limited manipulation space for Proglides and two wires, 3) use buddy wires if TAVR sheath advancement has failed over one wire and consider additional buddy wires from within the TAVR arteriotomy or ipsilateral protection site, and 4) use ipsilateral protection to avoid challenges of crossing over from contralateral iliofemoral. Although trans-EVAR TAVR remains somewhat unpredictable, these strategies may simplify and reduce the inherent failure rate of such procedures.
Abstract 13530: The Impact of COVID-19 Illness Risk on Physical Activity During the Pandemic
Authors: Wierenga Kelly L , Moore Scott E , Ofner Susan , Mulkey Malissa , Alwine Jennifer , Blake Hannah , Hacker Eileen , Chang Pei-Shiun , Pressler Susan J , Perkins Susan 
Published: June 2023

Introduction:
Risk related decision making for physical activity engagement changed during the pandemic. Importantly, life-threatening COVID-19 illness was riskier for adults with many chronic illnesses, including cardiovascular diseases. Determining physical activity level differences between people at high versus low risk for severe COVID-19 is critical for targeting future approaches for improving physical activity and cardiovascular health.

Hypotheses:
Between March 2020 and May 2021, compared to adults at low risk for severe COVID-19, adults at high risk have 1) greater odds of inactivity; and 2) in adults reporting physical activity, high risk is associated with lower metabolic equivalent of task (MET).

Methods:
This prospective observational study enrolled English-speaking US adults age 18 years and older.  Measures included demographic and health condition surveys, and the International Physical Activity Questionnaire (IPAQ) short form surveys at baseline, with IPAQ repeated at 3, 4, 7, 9, and 13 months. Inactivity was defined as reporting no activity bouts ≥ 10 minutes. Hypotheses testing used a two-part model of physical activity over time simultaneously fitting a logistic model of inactivity and a gamma model of total MET for the physically active while adjusting for age, gender, and race.

Results:
The sample included n = 687 (mean age = 42.4 ± 15.5, 78% women, 89% white). Odds of inactivity for COVID-19 high risk group was 2 to 4.1 times higher than that of low risk group at baseline and 13 months (Figure 1a). Physically active adults at high risk of severe COVID-19 had MET levels less than the low risk group at baseline (28%, p = .001), 3 (29%, p = .002), and 4 months (30%, p =.005), with no significant differences at later timepoints (see Figure 1b).

Conclusions:
Inactivity and MET level between group differences varied over time. Disproportionate odds of inactivity and lower MET levels was present primarily early in the pandemic in the high risk group.
Abstract 14713: Long-Term Clinical Outcomes in Patients With Chronic Total Occlusion of Single Coronary Artery Treated With Percutaneous Coronary Intervention versus Optimal Medical Therapy: A Ten-Year Follow Up Study
Authors: Kim Sungeun , Park Taek Kyu , Choi Seung-Hyuk 
Published: June 2023

INTRODUCTION : Only limited data are available and long term follow up studies are insufficient about optimal treatment in patients with chronic total occlusion of a single coronary artery.METHODS : A total of 2,024 patients with CTO were retrospectively enrolled in Samsung Medical Center CTO registry between March 2003 and February 2012 and followed-up for 10 years. Patients underwent coronary artery bypass graft (n = 477) and Patients with multi-vessel CTO (n = 1,112) were excluded. Finally patients with chronic total occlusion of a single coronary artery (n = 435) were analyzed. Divided into two groups, optimal medical group (OMT, n = 147) and percutaneous coronary intervention group (PCI, n = 288) in accordance with initial treatment strategy. Cox regression analysis and propensity score matching was performed to adjust for confounding factors. Primary outcome was cardiac death.RESULT : During the follow up 10 years, we identified that there were no significant differences between OMT group and PCI group in rate of cardiac death (adjusted HR, 0.57 [95% CI, 0.26-1.24]; P=0.16) as well as rate of major adverse cardiac event (adjusted HR, 0.79 [95% CI, 0.52-1.19]; P=0.26) . After propensity score matching analyses, OMT group and PCI group still have no significant differences in rate of cardiac death (adjusted HR, 0.54 [95% CI, 0.24-1.19]; P=0.13) and rate of MACE (adjusted HR, 0.97 [95% CI, 0.62-1.52]; P=0.89).CONCLUSION : This retrospective observational study supported that as an initial treatment strategy in patients of single vessel CTO, PCI did not decrease the rate of cardiac death or MACE.
KEYWORD : Chronic total occlusion, Optimal medical treatment, Percutaneous coronary intervention
Abstract 14821: Effect of Single Volatile Organic Compound Metabolites and Volatile Organic Compound Mixtures on Vascular Function
Authors: Stopforth Cameron , Sears Clara , Dials Justin , Srivastava Sanjay , Bhatnagar Aruni , Keith Rachel J 
Published: June 2023

Volatile organic compounds (VOCs) are ubiquitous environmental toxicants with pre-clinical evidence of decreased vascular health. Research to date has focused on single VOC metabolites and data is lacking on the effects on human vascular health. Many VOCs are strongly correlated with similar exposure sources. Though the compounding effects are poorly defined, they are likely to increase the overall toxicity. Therefore, we examined single VOC metabolites and mixtures’ association with flow mediated dilation (FMD), an index of vascular health.
We recruited adult participants into a CV risk cohort, aged 25-70 years, from 2018 and 2019. A panel of urinary VOC metabolites were measured in 308 non-smoking participants who had completed brachial artery FMD. Regression analysis of 16 VOC analytes was tested for associations with %FMD and models were adjusted for covariates selected a priori including age, sex, diabetes and ACE inhibitors. We examined the joint effect of MU, 3HPMA, CEMA, CYMA, DHBMA, 2HPMA, 2MHA, and AAMA mixtures on log-transformed %FMD using quantile-based g-computation models adjusted for the covariates above and for correlated VOC metabolites that were not associated with FMD in single metabolite analyses.
The mean %FMD was 7.1 % ± 4.7%. VOC metabolites that were predictors of decreased %FMD in fully adjusted models were 3HPMA (β=-1.275; 95% CI= -2.402, -0.148; p=0.027), CEMA (β= -1.204; 95% CI= -2.051; -0.357 p=0.006), AAMA (β=-1.125; 95% CI= -2.156, -0.094; p=0.033), 2HPMA (β= -1.035; 95% CI= -1.847, -0.222 p=0.013), and 2MHA (β=-0.623; 95% CI= -1.123, -0.124; p=0.015). Most VOC metabolites had fair to moderate correlations in bivariate analyses (Spearman correlation from 0.06 to 0.60). We found that a quartile increase in the VOC mixture was associated with 20% lower percent FMD (ψ -0.18; 95%CI= -0.35, -0.02; p=0.027) in adjusted models. We found the overall mixture effect was driven primarily by 3HPMA, followed by CYMA, CEMA, 2MHA, and AAMA. Therefore, the main driver of the association between the VOC mixture and decreased vascular function is acrolein and to a lesser extent acrylonitrile. Future research could focus on identifying sources of exposure to these VOCs to promote better vascular health among non-smokers.
Abstract 15226: Association of Estimated Pulse Wave Velocity to Mortality in Heart Failure With Reduced Ejection Fraction. Insights From the HF-Action Trial
Authors: Mazimba Sula , Woodhouse Rebecca , Oyinloye Tolu P , Lamp Josephine , Ashur Nicholas , Shisler David , Taylor Lauren , Abuannadi Mohammad , Phillips Steven , Ibrahim Sami , Hossack John A , Mehta Nishaki M , Breathett Khadijah , Boadu Akua , Bergin James , Kwon Younghoon , Bilchick Kenneth C 
Published: June 2023

Introduction:
Ventriculo-arterial coupling dynamics influence outcomes in heart failure (HF). Arterial stiffness (AS) is a key determinant of vascular load on the heart. We hypothesized that estimated pulse wave velocity (ePWV) would be associated with mortality.

Methods:
We analyzed the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) database for the association of ePWV with survival. ePWV was calculated using mean blood pressure (MBP) and Age using the equation: 9.587 – 0.402 х age + 4.560 х 10
–3
х age

2

– 2.621 х 10
–5
х age
2
х MBP + 3.176 х 10
–3
х age х MBP – 1.832 х 10
–2
х MBP. MBP was calculated as diastolic BP (DBP) + 0.4(SBP – DBP). Kaplan-Meier survival curves and Cox proportional hazards regression were used for analysis.

Results:
Among 768 patients (age 58.0 +/- 12.8 years, 31.8 % female), the median ePWV was 8.5 (IQR 7.2 to 10.2). There was a moderate correlation between ePWV and peak VO2 (r=-0.20, p<0.0001) and between ePWV and the six-minute walk duration (r=-0.20, p<0.0001). The unadjusted HR for ePWV and all-cause mortality was 1.15 per unit increase (95% CI 1.05-125). The unadjusted HRs for ePWV component covariates of age and MBP with all-cause mortality were 1.03 per year (95% CI 1.02-1.05, p < 0.0001) and 0.985 per mm Hg (95% CI 0.971-1.000, p=0.053), respectively. With adjustment by peak VO2 above or below the median in a multivariable model, increasing ePWV was still associated with a greater probability of all-cause mortality (HR 1.11 per unit increase, 95% CI 1.01-1.21, p=0.02). In the model with adjustment by the six-minute walk duration, risk associated with ePWV was similar (HR 1.09, 95% CI 0.998-1.120, p=0.056). Kaplan-Meier curves also demonstrated an increased risk for ePWV greater than the median value of 8.5 (Figure).

Conclusion:
ePWV is associated with all-cause mortality in stable HF patients. More studies are needed to assess the utility of ePWV as a therapeutic target in HF.